Biotech IV Monitor

VKTX — Viking Therapeutics Inc.

$4.0B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Viking Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is July 2027.

Next readoutJuly 2027in ~8 months
Upcoming readouts44 Phase 3
Market cap$4.0B
Cash & investments$960M~5 quarters at last loss rate
Recent 8-K filings1latest 2026-10-28

Upcoming readouts

Phase 3 VK2735
Weight Loss · NCT07104500
July 2027
Ongoing
Phase 3 VK2735
Weight Loss · NCT07104383
July 2027
Ongoing
Phase 3 VK2735
Weight Loss · NCT07868835
July 2028
Recruiting
Phase 3 VK2735 Oral
Weight Loss · NCT07868939
October 2028
Recruiting

Cash position

Viking Therapeutics Inc. reported $960M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $183M; at that rate the cash would last about 5 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-10-28

Discussion

No messages yet. If you follow VKTX, you can start the conversation.
Track VKTX in real time
See live implied volatility for VKTX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on VKTX
Contact — questions or corrections about VKTX: dukeupt@gmail.com